Tags : Xipere

Bausch Health In-Licenses Clearside’s Xipere (triamcinolone acetonide suprachoroidal injectable suspension)

Shots: Clearside to receive ~$20M prior to launch including an up front and is eligible to receive commercial & regulatory milestones on approval of Xipere for an additional indication and royalties on sales in the licensed territories Bausch Health to get an exclusive license to develop & commercialize Xipere for macular edema associated with uveitis […]Read More